Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Found a link to this page on FB
THIS PROGRAM IS DESIGNED TO PROVIDE YOU WITH THE KNOWLEDGE AND PRACTICAL SKILLS TO EASILY TRANSFER STEM CELL TECHNIQUES TO YOUR OFFICE
WHY THIS COURSE IS DIFFERENT?
We’ve given our most care and attention to providing a total solution that comprises top level theoretical training, an intense amount of hands-on experience in the lab and with patients, as well as professional support and, of course, all the necessary equipment and materials.
Our training course teaches you everything you need to know to add adult stem cell based procedures to your existing practice, or confidently transition to a regenerative medicine center.
https://www.stemcelltraining.net/hands-on-course/
Long LAHO,
~Magnus
Lans Holding website looks nice
http://www.lans.holdings/index.html
Long LAHO/GSCG
~Magnus
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
https://stemcellorthopedic.com/about-us/news/global-stem-cells-group-honor-joseph-purita/
MIAMI, Aug. 16, 2016
We are investing in Global Stem Cell Group and not Lans Holding.
Invest in what you know and know what you're investing in!!!!
Long LAHO,
~Magnus
Is a Promissory Note Legally Binding?
Promissory Notes Are Legal Contracts
A promissory note or promissory letter is a legal instrument similar in nature to any common law contract. In order for a contract to be enforceable, it must contain certain legal conditions such as an offer and an acceptance of that offer. Contracts indicate the type and amount of payment for services or goods rendered. In the case of a legal promissory note, the contract will be shaped around the amount of money or capital loaned and the terms of repayment of the promissory note.
As with any contract, the promissory note will contain all the terms and conditions associated with the agreement that have been established between the two parties. It will detail the total amount of money or capital loaned, the interest rate that is charged, and the timeline for repayment. When all of these conditions are addressed in the promissory note details and it is signed by both parties, the promissory note meets all the elements of a legally binding contract.
https://help.legalnature.com/articles/is-a-promissory-note-legally-binding
Deirdre Leane sold Chanbond LLC to UnifiedOnline Inc. and they closed the deal with a Promissory Note. The deal was closed 10/27/2015
Long UOIP,
~Magnus
I-Glow, it's only meaningless chatter because you do not agree with the facts. The deal has been closed and was signed. Read the copy of the purchase agreement which is on the SEC website.
https://www.sec.gov/Archives/edgar/data/1097718/000135448815005300/uoip_ex102.htm
Long UOIP,
~Magnus
I-Glow, all of your concerns have been addressed in this post
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150464637
Which has also been made sticky
Let me know your thoughts and Long UOIP,
~Magnus
Some background on the UnifiedOnline Inc purchase of Chanbond LLC
1. Deirdre Leane sold Chanbond LLC to UnifiedOnline Inc.
This Agreement (this "Agreement"), is made as of October 27, 2015 (the "Effective Date"), by and among Deirdre Leane, an individual with an address of 2525 Carlisle St., Suite 439, Dallas, Texas 75201 ("Seller"), ChanBond, LLC, a Delaware limited liability company, of 2633 McKinney Ave., Suite 130-501, Dallas, Texas 75204 ("ChanBond") and UnifiedOnline, Inc., a Delaware corporation, of 4126 Leonard Drive, Fairfax, Virginia 22030 ("Purchaser"). The parties to this Agreement shall be referred to collectively herein as the "Parties" and separately as a "Party".
2. Chanbond has been legally delivered to UnifiedOnline Inc.
Sale and Purchase of Interests
Subject to the terms and conditions hereof, at the Closing, Seller shall sell, assign, transfer, convey and deliver to Purchaser ChanBond and Purchaser shall purchase and accept the assignment, transfer conveyance and delivery of ChanBond from the Seller. Closing of Sale and Purchase of Interests; Covenants of Purchaser
2.1 Closing. The sale, assignment, transfer and delivery of ChanBond by the Seller and the purchase thereof by the Purchaser, shall take place at a closing, to be held remotely via the exchange of documents and signatures within one business day following the execution of this Agreement (the "Closing" and the "Closing Date," respectively).
2.2 Transactions at Closing. At the Closing, the following transactions shall occur, which transactions shall be deemed to take place simultaneously and no transaction shall be deemed to have been completed or any document delivered until all such transactions have been completed and all required documents delivered:
2.2.1 The Seller shall duly execute an interest assignment deed in the fonn
attached hereto as Schedule 2.2.1 (the "Transfer Deed") and shall deliver their respective Transfer Deed to Purchaser;
2.2.2 At Closing, ChanBond shall appoint William R. Carter, Jr. as sole
manager ("Manager") and thereafter Manager shall have sole and exclusive authority over the business of ChanBond.
2.2.3 Purchaser shall deliver to the Seller copies of resolutions of its Board of Directors in the form attached hereto as Schedule 2.2.3, approving., inter alia, the transactions contemplated hereunder and the issuance of the Shares (as defined below) by Purchaser to Seller.
2.2.4 The Collateral Agreements shall have been executed and delivered by the respective parties thereto.
2.2.5 Purchaser shall deliver to the Seller a validly executed share certificate for the Shares (as defined below) issuable in the name of the Seller in such amounts as shall be directed by Seller not less than 72 hours after the Closing.
2.2.6 Purchaser shall deliver to Seller evidence that each Required Approval (as defused below) has been obtained.
2.2.7 Seller, ChanBond and Purchaser shall have entered into the Common
Interest Agreement, in the form attached hereto as Schedule 2.2.7.
2.2.8 Purchaser shall deliver to Seller the Promissory Note (as defined below), in the form attached hereto as Schedule 2.2.
3. William R. Carter, Jr. does not own Chanbond LLC - William R. Carter, Jr. as sole manager ("Manager") and thereafter Manager shall have sole and exclusive authority over the business of ChanBond.
4. I highly doubt William R. Carter, Jr. is paying for the legal cost. According to the Chanbond LLC Contract. Chanbond LLC entered into a contract with Mishcon de Reya 4/20/15 and Bentham IMF Litigation Funding 9/9/15. This purchase agreement was made 10/27/2015
ChanBond, LLC - Mishcon de Reya Retention Agreement dated April 20, 2015
ChanBond, LLC — Bentham IMF Litigation Funding Agreement dated September 9, 2015
Check out: https://www.benthamimf.com/what-we-do/intellectual-property-funding
5. Payments/Considerations for Chanbond LLC failure to pay the $5MM on October 27, 2020 does not mean Deirdre Leane takes Chanbond LLC back but instead UnifiedOnline Inc will pay a monthly penalty until the promissory note is completed.
3.1 Cash Payment . Five million U.S. Dollars ($5,000,000) payable on or before October 27, 2020 (the "Cash Payment"). The obligation to make the Cash Payment shall be evidenced by Purchaser's promissory note (the "Promissory Note") in the form of Schedule 2.2.8 attached hereto; and
3.2 Shares Payment. Forty-four million, seven hundred thousand (44,700,000) shares of Purchaser's Common Stock (the "Shares") par value of $0.001 each.
however, that if this Note is not paid in full by the Maturity Date, the aggregate principal amount of this Note shall be increased by Twenty Five Thousand Dollars ($25,000.00) for each month such payment is delayed (or pro rata portion thereof) until paid in full (the "New Principal Balance").
....
....
....
Upon the occurrence of an Event of Default, the entire unpaid and outstanding indebtedness due under this Note shall be immediately due and payable without notice and Holder shall be entitled to such additional rights and remedies as are provided by law.
Until the Note is paid in full, the Company shall be obligated to make payments on this Note to the Holder from 100% of any Net Revenues (as defused below) within thirty (30) calendar days after each calendar month commencing with the calendar month ending October 31, 2015.
6. Chanbond LLC and UnifiedOnline Inc share a legal bond.
"Net Revenues" shall mean the total aggregate Gross Recoveries less the total aggregate amount of costs and expenses - incurred by or on behalf of the Company in connection with the monetization, enforcement and/or sale of the Assigned Patent Rights of the ChanBond, LLC patent portfolio (described in Exhibit A) - which are exclusively limited to: (a) the reasonable fees and expenses of litigation counsel; (b) the reasonable fees and expenses of licensing counsel (c)the reasonable fees and expenses of any re-examination or other patent prosecution counsel; (d)reasonable expert fees, court costs, deposition costs and other reasonable costs and expenses related to the maintenance, prosecution, enforcement, and licensing of the Patents; and (e) the reasonable fees and expenses of any other advisors or agents which the Parties mutually agree are required and the repayment of litigation financing.
SCHEDULE 2.2.7
Common Interest Agreement
THIS COMMON INTEREST AGREEMENT ("Agreement") is entered into as of April 9, 2015, by and among ChanBond, LLC (the "Company") having its principal offices at 2633 McKinney Avenue, Suite 130-501, Dallas, Texas 75204; UnifiedOnline, Inc. ("UnifiedOnline"), having its principal offices at 4126 Leonard Drive, Fairfax, Virginia 22030; and Deirdre Leane ("Leane"), located at 2525 Carlisle Street, Suite 439, Dallas, Texas 75201.
i. Background.
1.1. Company, Unified and Leane are sometimes referred to herein as a "party" or the "parties" and are presently negotiating the closing of an agreement under which UnifiedOnline will purchase Company from Leane and continue to enforce and license patents and related rights owned by the Company "IP Rights" and the "Patent Matters" respectively).
1.2. The parties have a common legal interest in upholding the validity and enforceability of the IP Rights, for purposes of enforcement. The parties anticipate they will enforce inherent rights of the IP Rights against third parties through litigation. The parties have agreed to treat their communications and those of their counsel relating to the Patent Matters as protected by the common interest doctrine. Furtherance of the Patent Matters requires the exchange of proprietary documents and information, the joint development of legal strategies and the exchange of privileged information and attorney work product developed by the parties and their respective counsel.
2. Common Interest.
2.1. The parties have a common, joint and mutual legal interest in the monetization of valid and enforceable patents. In furtherance of that common interest, the parties will cooperate with each other, to the extent permitted by law, to share information protected by the attorney-client privilege, the work product doctrine, or other applicable privilege or immunity with respect to the Patent Matters. Any counsel or consultant retained by a party or their counsel to assist in the Patent Matters shall be bound by, and entitled to the benefits of this Agreement.
Set your minds at ease and review the purchase agreement for yourself.
https://www.sec.gov/Archives/edgar/data/1097718/000135448815005300/uoip_ex102.htm
Long UOIP,
~Magnus
Evil,
Mediacom has included a boiler plate statement in the 10-K's for as far back as I can see and they don't ever mention anything in their 10-Q's
Long UOIP,
~Magnus
10-K Mar 8, 2019
https://mediacomcommunicationscorporation.gcs-web.com/node/12991/html
Our business depends on certain intellectual property rights and on not infringing on the intellectual property rights of others.
We rely on our copyrights, trademarks and trade secrets, as well as licenses and other agreements with our vendors and other parties, to use our technologies, conduct our operations and sell our products and services. Third-party firms have in the past, and may in the future, assert claims or initiate litigation related to patent, copyright, trademark, and other intellectual property rights to technologies and related standards that are relevant to us. These assertions have increased over time as a result of our growth and the general increase in the pace of patent claims assertions, particularly in the United States. Recently, the number of intellectual property infringement claims has been increasing in the communications and entertainment fields, and from time to time, we have been party to litigation alleging that certain of our services or technologies infringe upon the intellectual property rights of others. Because of the large number of patents in the networking field, the secrecy of some pending patents and the rapid rate of issuance of new patents, it is not economically practical or, in some cases, possible to determine in advance whether a product or any of its components infringes or will infringe on the patent rights of others. Asserted claims and/or initiated litigation can include claims against us or our manufacturers, suppliers, or customers, alleging infringement of their proprietary rights with respect to our existing or future products and/or services or components of those products and/or services. Regardless of the merit of these claims, they can be time-consuming to defend; result in costly litigation and diversion of technical and management personnel; and require us to develop a non-infringing technology or enter into license agreements. There can be no assurance that licenses will be available on acceptable terms and conditions, if at all, or that any indemnification by our suppliers will be adequate to cover our costs if a claim were brought directly against us or our customers. Furthermore, because of the potential for high monetary awards that are not predictable, it is not unusual to find even arguably unmeritorious claims settled for significant amounts.
If any infringement or other intellectual property claim made against us by any third-party is successful, if we are required to indemnify a customer with respect to a claim against the customer, or if we fail to develop non-infringing technology or license the proprietary rights on commercially reasonable terms and conditions, our business, results of operations, and financial condition could be adversely affected.
I think COMM going bankrupt will help us. The 13 cable companies will loose their safety net (cockiness).
Long UOIP,
~Magnus
Dr. Leslie Mesen MD
ISSCA Director for Central America and the Caribbean en ISSCA International Society for Stem Cell Application
https://www.linkedin.com/in/dr-leslie-mesen-md-47a26655/
Long LAHO,
~Magnus
The ISSCA Podcast: Regulaciones FDA en terapias celulares y Hormonas Bioidénticas
Mediacom released their 10-K without any mention in their legal concerns
https://mediacomcommunicationscorporation.gcs-web.com/sec-filings
Long UOIP,
~Magnus
That is a very impressive array of doctors on the advisory board.
http://www.stemcellsgroup.com/advisory-board/
Long LAHO,
~Magnus
News is coming and shorts will be caught with their hands in the cookie jar.
OTC Short Report
https://www.otcshortreport.com/company/LAHO
Long LAHO,
~Magnus
Global Stem Cell Group posted a second video today
The lab is the group’s first facility of its kind and will produce neonatal tissue-derived products such as exosomes, cord blood derived stem cells, and amniotic fluid derived products.
http://www.stemcellsgroup.com/author/bnovas/
Global Stem Cells Group to Break Ground on New Lab in Mexico
TUESDAY, 06 AUGUST 2019 BY BENITO NOVAS
The new Stem Cells Lab is set to break ground in 2020, providing affordable regenerative medicine products to Latin America and the US
MIAMI LAKES, Florida—The Global Stem Cells Group today announced that it will be expanding its research and production efforts with a new lab in Mexico. The lab is the group’s first facility of its kind and will produce neonatal tissue-derived products such as exosomes, cord blood derived stem cells, and amniotic fluid derived products. Groundbreaking is slated for January 2020.
The Global Stem Cells Group is a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine. To further the group’s mission, the new lab will fill a much-needed research and production niche in the regenerative medicine field and will be especially beneficial to physicians practicing in Latin America and the United States.
The lab will strictly adhere to all Good Manufacturing Practice (GMP) standards. Although the lab will be located in Mexico, all products will be procured and processed according to the standards and regulations set forth by the American Association of Tissue Banks (AATB) and the United States Food and Drug Administration (FDA). All tissue will come from local donors, with the lab strictly adhering to donor ethics and the FDA’s approved serological screening policies.
In addition to producing neonatal tissue derived products, the lab will also facilitate clinical trials to explore the safety and efficacy of new regenerative medicine products before they launch. The lab will also serve as a teaching and learning center for doctors and scientists across the globe looking to learn more about stem cells protocols.
“The Global Stem Cells Group is committed to facilitating stem cell research and medicine across the globe,” said Benito Novas, CEO of the Global Stem Cells Group. “Our new lab in Mexico will allow us to make good on this mission by delivering more affordable neonatal tissues derived products to doctors across Latin America and the US. As a result, more patients will find relief from debilitating degenerative diseases.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
Global Stem Cells Group to Break Ground on New Lab in Mexico
https://www.prunderground.com/global-stem-cells-group-to-break-ground-on-new-lab-in-mexico/00162800/
Global Stem Cells Group to Break Ground on New Lab in Mexico
Industry: Healthcare
The new Stem Cells Lab is set to break ground in 2020, providing affordable regenerative medicine products to Latin America and the US
Miami Lakes, FL (PRUnderground) August 6th, 2019
The Global Stem Cells Group today announced that it will be expanding its research and production efforts with a new lab in Mexico. The lab is the group’s first facility of its kind and will produce neonatal tissue-derived products such as exosomes, cord blood derived stem cells, and amniotic fluid derived products. Groundbreaking is slated for January 2020.
The Global Stem Cells Group is a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine. To further the group’s mission, the new lab will fill a much-needed research and production niche in the regenerative medicine field and will be especially beneficial to physicians practicing in Latin America and the United States.
The lab will strictly adhere to all Good Manufacturing Practice (GMP) standards. Although the lab will be located in Mexico, all products will be procured and processed according to the standards and regulations set forth by the American Association of Tissue Banks (AATB) and the United States Food and Drug Administration (FDA). All tissue will come from local donors, with the lab strictly adhering to donor ethics and the FDA’s approved serological screening policies.
In addition to producing neonatal tissue derived products, the lab will also facilitate clinical trials to explore the safety and efficacy of new regenerative medicine products before they launch. The lab will also serve as a teaching and learning center for doctors and scientists across the globe looking to learn more about stem cells protocols.
“The Global Stem Cells Group is committed to facilitating stem cell research and medicine across the globe,” said Benito Novas, CEO of the Global Stem Cells Group. “Our new lab in Mexico will allow us to make good on this mission by delivering more affordable neonatal tissues derived products to doctors across Latin America and the US. As a result, more patients will find relief from debilitating degenerative diseases.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
ISSCA Offers Stem Cells Certification at London’s Chandos House, a Royal Society of Medicine Partner
https://www.prunderground.com/issca-offers-stem-cells-certification-at-londons-chandos-house-a-royal-society-of-medicine-partner/00162806/
ISSCA Offers Stem Cells Certification at London’s Chandos House, a Royal Society of Medicine Partner
Industry: Healthcare
The intensive workshop to be held in the locale of one of the world’s most distinguished medical education providers
Miami Lakes, FL (PRUnderground) August 6th, 2019
The International Society for Stem Cells Applications (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has announced a new stem cells certification workshop in London. The two-day workshop, held DATES, will take place at London’s Chandos House. Chandos House is a partner of the Royal Society of Medicine, a global leader in postgraduate medical education.
With the workshop taking place in a prestigious locale for medical education, attendees can expect to network and learn from the industry’s most respected leaders. Physicians participating in the intensive two-day workshop will take advantage of expert reviews of stem cells biology, characterizations and regenerative properties of cells and cell products, cytokines, and growth factors.
Additionally, attendees will gain a clear understanding of laboratory processes in product validation, cryopreservation, and quality control. Facilitators will also discuss the regulatory landscape in detail with added sessions focusing on practice management and patient acquisition.
ISSCA is teaming up with London-based bioscience company Ludger (https://ludger.com) to provide expanded educational opportunities during the UK workshop. Ludger representatives will offer three additional learning sessions, adding to ISSCA’s traditional certification agenda. Ludger’s sessions include
Chronic inflammation as a critical parameter in stem cells therapies
Why biomarkers of acute inflammation cannot reliably measure chronic inflammation
Glyhealth blood glycomics biomarkers for reliable measurement of CI
“To host one of our certification sessions in London in the shadows of the Royal Society of Medicine is an incredible honor,” said Benito Novas, Vice President of Public Relations for ISSCA. “We strive to offer innovative educational opportunities to practitioners in the regenerative medicine field, and we are excited to bring our renowned stem cells training certification to London’s medical community.”
To learn more about the ISSCA, its latest efforts, and upcoming events, visit https://www.issca.us/.
About International Society for Stem Cells Applications
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine. Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative
medicine and make it available to benefit patients both nationally and globally.
For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com
New video posted "ISSCA certification Training Course"
I like this chart.
Long UOIP,
~Magnus
I am also hoping that Judge Andrews now schedules the court date. The judge did say he wouldn't make the date until after this appeal.
My opinion
1. If the Chanbond v Cisco ruling is reversed then Judge Andrews will push for a settlement without a trail.
2. If the Chanbond v Cisco ruling is denied or sent back to PTAB, Chanbond will not peruse a trail. I believe they will leave it and go to court against the 13 with the two patents that are proven ours.
3. I believe CAFC reply will be this month and Chanbond should have a court date between September 2019 and March 2020
Long UOIP,
~Magnus
I also wondered why Stacey wasn't asked more questions and I was later told that he didn't have to speak much, he didn't make the appeal. It was Mr Whitman that had to bring evidence of reason for reversal.
Long UOIP,
~Magnus
Being there in person they did not show any annoyance on their faces. Judge Chen carries himself with an air of confidence, body language had him leaning back in his chair. Judge Lori had a glazed look on his face and didn't look like he understood the topic and was more concerned with the time. Judge Stoll listened intently and looked generally interested. Her body language had her leaning forward listening. Interesting mix
Our case was the second one heard, we came right after Henny Penny. That lawyer was dry, slow, and could have aggravated even Judge Lori LOL!!!!
Long UOIP,
~Magnus
After listening to the audio file I question my court room review. Gonna remove my post till I confirm what I wrote.
Long UOIP,
Magnus
Correct BRI has to do with ISDN. But why did Judge Stoll mention it during Mr Whitman’s rebuttal?
I will listen to the audio.
But it could have been in reference to where Cisco previous ISDN modems were being compared to this 822 patent. Something to do with RF Channels. Maybe Judge Stoll was trying to help out Mr Whitman
Long UOIP,
Magnus
Link to the audio of todays CAFC
http://www.cafc.uscourts.gov/oral-argument-recordings
2019-08-06
2018-1886
ChanBond, LLC v. Cisco Systems, Inc.
2018-1886.mp3
Long UOIP,
~Magnus
Many of family dinners with the radio on and "The rest of the story"
Good ole Howie
If he was with us today and was a stock commentator, the things he would be saying about comm LOL!!!
I can remember my dad yelling at the tv whenever Howard was one.
Long UOIP,
~Magnus
Comm taking on more water
Aug 5, 2019 9:57 EST
$13.30 -0.43
Long UOIP,
~Magnus
LONGS Keep holding
Aug 5, 2019
9:54 EST
BID .00070 x 157,989,605
ASK .00080 x 18,660,814
Long LAHO
~Magnus
It is odd and the majority of them are either 2,500 or 22,500 shares
Long LAHO,
~Magnus
AllinFun already addressed this 5/16/2019
https://investorshub.advfn.com/boards/replies.aspx?msg=148864289
'565 and '679 crushed every claim in the PTAB. '822 was the only one to get 8 claims against it from that Cisco IPR that we are appealing and waiting on a decision from the Federal Circuit whether it gets to go back to the PTAB for review or not. The '679 is tough as nails and has the PTAB fully supporting it going into any trial so I am not as worried as I might have been had the new theory pertained to the '822 which only has 8 claims against it.
The more and more you think about this current situation - the more telling it is that this was just another delay tactic for them. Gets them a little more time before the Daubert hearing. Stalling hard and probably having Carter's line go off the hook to settle this up.
Long UOIP,
~Magnus
Chanbond filed for the patents in question between Feb. 1, 2008 and Nov. 20, 2012
The patent that you reference was filed Dec. 9, 2016 and was for "the generation of OFDM signals for DOCSIS 3.1"
Please get your facts straight.
Long UOIP,
~Magnus
WOW has released their 10-K today
https://ir.wowway.com/investor-relations/sec-filings/default.aspx
Very innocuous disclaimer in their 10-K
"The Company is party to various legal proceedings arising in the normal course of its business covering a wide range of
matters and types of claims including, but not limited to, general contracts, billing disputes, rights of access, programming, taxes,
fees and surcharges, consumer protection, trademark and patent infringement, employment, regulatory, tort, claims of competitors
and disputes with other carriers."
Long UOIP,
~Magnus
You are very kind, thank you
Long UOIP,
~Magnus
I see what you mean about the purchase in June of 2016
https://www.multichannel.com/news/altice-usa-makes-impressive-nyse-debut-413638
Altice USA, a subsidiary of European telecom giant Altice N.V., priced its IPO Wednesday night at $30 per share. The cable company, which bought Suddenlink Communications in December 2015 and Cablevision Systems in June 2016, offered about 63.9 million shares to the public, raising about $1.9 billion.
That is a lot of money
Long UOIP,
~Magnus
Exactly, but I didn’t understand the last one from Charter and I do not understand this one from Altice / CableVision
Long UOIP,
Magnus
I thought Altice already owned CableVision and that this was another note selling deal like Charter did on July 10th
Long UOIP,
~Magnus
Thank you Tony,
and Press release states
CommScope Holding Co (NASDAQ:COMM) stock hit a yearly low of $14.27. The stock was down 0.62% for the day.
Long UOIP,
~Magnus
Deutsche Bank to pay CSC Holdings $1,000,000,000
Is that what the exhibit states? https://www.sec.gov/Archives/edgar/data/1702780/000162828019008729/seniornotesindenturedue2030.htm
I do not understand these particular 8-K's
Long UOIP,
~Magnus